American Association for Cancer Research
10780432ccr120896-sup-methfigleg.pdf (106.98 kB)

Supplementary Methods and Figure Legend from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor

Download (106.98 kB)
journal contribution
posted on 2023-03-31, 17:01 authored by Magalie Dosset, Yann Godet, Charline Vauchy, Laurent Beziaud, Yu Chun Lone, Christine Sedlik, Christelle Liard, Emeline Levionnois, Bertrand Clerc, Federico Sandoval, Etienne Daguindau, Simon Wain-Hobson, Eric Tartour, Pierre Langlade-Demoyen, Christophe Borg, Olivier Adotévi

PDF file - 106K



Purpose: To evaluate CD4+ helper functions and antitumor effect of promiscuous universal cancer peptides (UCP) derived from telomerase reverse transcriptase (TERT).Experimental Design: To evaluate the widespread immunogenicity of UCPs in humans, spontaneous T-cell responses against UCPs were measured in various types of cancers using T-cell proliferation and ELISPOT assays. The humanized HLA-DRB1*0101/HLA-A*0201 transgenic mice were used to study the CD4+ helper effects of UCPs on antitumor CTL responses. UCP-based antitumor therapeutic vaccine was evaluated using HLA-A*0201–positive B16 melanoma that express TERT.Results: The presence of a high number of UCP-specific CD4+ T cells was found in the blood of patients with various types of cancer. These UCP-specific T cells mainly produce IFN-γ and TNF-α. In HLA transgenic mice, UCP vaccinations induced high avidity CD4+ TH1 cells and activated dendritic cells that produced interleukin-12. UCP-based vaccination breaks self-tolerance against TERT and enhances primary and memory CTL responses. Furthermore, the use of UCP strongly improves the efficacy of therapeutic vaccination against established B16-HLA-A*0201 melanoma and promotes tumor infiltration by TERT-specific CD8+ T cells.Conclusions: Our results showed that UCP-based vaccinations strongly stimulate antitumor immune responses and could be used to design efficient immunotherapies in multiple types of cancers. Clin Cancer Res; 18(22); 6284–95. ©2012 AACR.

Usage metrics

    Clinical Cancer Research



    Ref. manager